Orum Therapeutics a biotechnology company listed on the Korean stock exchange, has appointed Dr. Chad May as its new Chief Scientific Officer (CSO). The company is known for developing advanced medicines called degrader-antibody conjugates (DACs), which are designed to target and break down disease-causing proteins.
Dr. Chad May has over 20 years of experience in cancer and immune system research. He has worked on developing advanced treatments such as antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapies, taking them from early research stages to clinical testing in patients.
“Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “His leadership experience in ADCs, T-cell engagers, and structure-driven platform design aligns with Orum’s commitment to precision engineering the next generation of degrader-antibody conjugates. Chad’s expertise strengthens our position as a leader in DAC innovation and supports our progress toward meaningful clinical milestones.”
As Chief Scientific Officer, Dr. Chad May will lead Orum’s research and development work. He will guide the company’s scientific direction and help decide which new medicines the company should develop next.
He will also support the improvement of Orum’s own DAC technology, manage early research and testing before human trials, and play a key role in growing the company’s future treatment pipeline and technology innovation.
“The opportunity to join Orum at this stage of growth is incredibly compelling,” said Dr. May. “The Company’s Dual-Precision Targeted Protein Degradation approach provides a powerful foundation for creating new classes of degraders guided by antibody specificity. I am excited to work closely with the talented scientific and leadership teams to advance Orum’s DAC platforms, expand therapeutic applications across cancer and other serious diseases, and drive the next wave of innovation in degrader-antibody conjugates.”
Orum Therapeutics is a public biotechnology company that develops advanced medicines designed to target and break down disease-causing proteins inside cells. It uses a special technology that combines precise antibody targeting with protein-degrading science to create a new type of treatment called degrader antibody conjugates (DACs), mainly for cancer and other serious diseases.
The company is currently working on programs that target a protein called GSPT1 and is also developing new protein-degrading medicines to treat diseases that are difficult to cure. Orum Therapeutics operates in Lexington, Massachusetts (USA) and Daejeon, South Korea.
Read More- Qbeat Quantum Fund Secures $20 Million in First Funding Round
